Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 Aug;62(2):235–240. doi: 10.1172/JCI109121

A common uptake system for serotonin and dopamine in human platelets.

G S Omenn, L T Smith
PMCID: PMC371758  PMID: 670392

Abstract

Kinetic and pharmacologic properties of uptake of serotonin and dopamine by normal human platelets have been investigated to test whether platelets can be employed as a model system for the reuptake of serotonin and dopamine in brain. Uptake of serotonin into platelets closely resembles reuptake of serotonin into serotonergic neurons. In contrast, uptake of dopamine into platelets appears to be mediated inefficiently via the specific serotonin uptake mechanism, based upon several lines of evidence. Serotonin and dopamine compete with each other, Antidepressant drugs, which are competitive inhibitors of uptake of both of these neurotransmitters, act at the same concentration of drug despite large differences in the Km values. Serotonin antagonists inhibit both serotonin and dopamine uptake. Finally, a serotonin-specific uptake inhibitor (fluoxetine) blocks dopamine, as well as serotonin, uptake.

Full text

PDF
235

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AXELROD J. THE METABOLISM, STORAGE, AND RELEASE OF CATECHOLAMINES. Recent Prog Horm Res. 1965;21:597–622. [PubMed] [Google Scholar]
  2. Aminoff M. J., Trenchard A., Turner P., Wood W. G., Hills M. Plasma uptake of dopamine and 5-hydroxytryptamine and plasma-catecholamine levels in patients with Huntington's chorea. Lancet. 1974 Nov 9;2(7889):1115–1116. doi: 10.1016/s0140-6736(74)90873-3. [DOI] [PubMed] [Google Scholar]
  3. Barbeau A., Campanella G., Butterworth R. F., Yamada K. Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease. Neurology. 1975 Jan;25(1):1–9. doi: 10.1212/wnl.25.1.1. [DOI] [PubMed] [Google Scholar]
  4. Bayer S. M., McCoy E. E. A comparison of the serotonin and ATP content in platelets from subjects with Down's syndrome. Biochem Med. 1974 Mar;9(3):225–232. doi: 10.1016/0006-2944(74)90056-8. [DOI] [PubMed] [Google Scholar]
  5. Born G. V., Smith J. B. Uptake, metabolism and release of (3H)-adrenaline by human platelets. Br J Pharmacol. 1970 Aug;39(4):765–778. doi: 10.1111/j.1476-5381.1970.tb09903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boullin D. J., O'Brien R. A. Abnormalities of 5-hydroxytryptamine uptake and binding by blood platelets from children with Down's syndrome. J Physiol. 1971 Jan;212(2):287–297. doi: 10.1113/jphysiol.1971.sp009325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Boullin D. J., O'Brien R. A. Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with L-DOPA. Br J Pharmacol. 1970 Aug;39(4):779–788. doi: 10.1111/j.1476-5381.1970.tb09904.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Boullin D. J., O'Brien R. A. Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with L-DOPA. Br J Pharmacol. 1970 Aug;39(4):779–788. doi: 10.1111/j.1476-5381.1970.tb09904.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Boullin D. J., O'Brien R. A. The metabolism of 5-hydroxytryptamine by blood platelets from children with mongolism. Biochem Pharmacol. 1973 Jul 1;22(13):1647–1651. doi: 10.1016/0006-2952(73)90031-2. [DOI] [PubMed] [Google Scholar]
  10. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  11. Coyle J. T., Snyder S. H. Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J Pharmacol Exp Ther. 1969 Dec;170(2):221–231. [PubMed] [Google Scholar]
  12. Horn A. S., Cuello A. C., Miller R. J. Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity. J Neurochem. 1974 Feb;22(2):265–270. doi: 10.1111/j.1471-4159.1974.tb11589.x. [DOI] [PubMed] [Google Scholar]
  13. Hunt P., Kannengiesser M., Raynaud J. Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J Pharm Pharmacol. 1974 May;26(5):370–371. doi: 10.1111/j.2042-7158.1974.tb09294.x. [DOI] [PubMed] [Google Scholar]
  14. Lidbrink P., Jonsson G., Fuxe K. The effect of imipramine-like drugs and antihistamine drugs on uptake mechanisms in the central noradrenaline and 5-hydroxytryptamine neurons. Neuropharmacology. 1971 Sep;10(5):521–536. doi: 10.1016/0028-3908(71)90018-9. [DOI] [PubMed] [Google Scholar]
  15. Lott I. T., Chase T. N., Murphy D. L. Down's syndrome: transport, storage, and metabolism of serotonin in blood platelets. Pediatr Res. 1972 Sep;6(9):730–735. doi: 10.1203/00006450-197209000-00006. [DOI] [PubMed] [Google Scholar]
  16. Murphy D. L., Cahan D. H., Molinoff P. B. Occurrence, transport, and storage of octopamine in human thrombocytes. Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):587–593. doi: 10.1002/cpt1975185part1587. [DOI] [PubMed] [Google Scholar]
  17. Murphy D. L., Mendell J. R., Engel W. K. Serotonin and platelet function in Duchenne muscular dystrophy. Arch Neurol. 1973 Apr;28(4):239–242. doi: 10.1001/archneur.1973.00490220047006. [DOI] [PubMed] [Google Scholar]
  18. Omenn G. S., Smith L. Platelet uptake of serotonin and dopamine in Huntington disease. Neurology. 1978 Mar;28(3):300–303. doi: 10.1212/wnl.28.3.300. [DOI] [PubMed] [Google Scholar]
  19. PARE C. M., SANDLER M., STACEY R. S. 5-Hydroxytryptamine deficiency in phenylketonuria. Lancet. 1957 Mar 16;272(6968):551–553. doi: 10.1016/s0140-6736(57)90920-0. [DOI] [PubMed] [Google Scholar]
  20. Paasonen M. K. Release of 5-hydroxytryptamine from blood platelets. J Pharm Pharmacol. 1965 Nov;17(11):681–697. doi: 10.1111/j.2042-7158.1965.tb07590.x. [DOI] [PubMed] [Google Scholar]
  21. Pletscher A. Metabolism, transfer and storage of 5-hydroxytryptamine in blood platelets. Br J Pharmacol Chemother. 1968 Jan;32(1):1–16. doi: 10.1111/j.1476-5381.1968.tb00423.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shaskan E. G., Snyder S. H. Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. J Pharmacol Exp Ther. 1970 Nov;175(2):404–418. [PubMed] [Google Scholar]
  23. Smith L. T., Hanson D. R., Omenn G. S. Comparisons of serotonin uptake by blood platelets and brain synaptosomes. Brain Res. 1978 May 12;146(2):400–403. doi: 10.1016/0006-8993(78)90987-3. [DOI] [PubMed] [Google Scholar]
  24. Sneddon J. M. Blood platelets as a model for monoamine-containing neurones. Prog Neurobiol. 1973;1(2):151–198. doi: 10.1016/0301-0082(73)90019-1. [DOI] [PubMed] [Google Scholar]
  25. Snyder S. H., Coyle J. T. Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther. 1969 Jan;165(1):78–86. [PubMed] [Google Scholar]
  26. Solomon H. M., Spirt N. M., Abrams W. B. The accumulation and metabolism of dopamine by the human platelet. Clin Pharmacol Ther. 1970 Nov-Dec;11(6):838–845. doi: 10.1002/cpt1970116838. [DOI] [PubMed] [Google Scholar]
  27. Tuomisto J. A new modification for studying 5-HT uptake by blood platelets: a re-evaluation of tricyclic antidepressants as uptake inhibitors. J Pharm Pharmacol. 1974 Feb;26(2):92–100. doi: 10.1111/j.2042-7158.1974.tb09231.x. [DOI] [PubMed] [Google Scholar]
  28. Tuomisto J., Tukiainen E. Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature. 1976 Aug 12;262(5569):596–598. doi: 10.1038/262596a0. [DOI] [PubMed] [Google Scholar]
  29. Tuomisto L., Tuomisto J., Smissman E. E. Dopamine uptake in striatal and hypothalamic synaptosomes: conformational selectivity of the inhibition. Eur J Pharmacol. 1974 Mar;25(3):351–361. doi: 10.1016/0014-2999(74)90265-9. [DOI] [PubMed] [Google Scholar]
  30. Weiss H. J. Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med. 1975 Sep 11;293(11):531–541. doi: 10.1056/NEJM197509112931105. [DOI] [PubMed] [Google Scholar]
  31. Weiss H. J., Tschopp T. B., Rogers J., Brand H. Studies of platelet 5-hydroxytryptamine (serotonin) in storage pool disease and albinism. J Clin Invest. 1974 Aug;54(2):421–433. doi: 10.1172/JCI107778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wong D. T., Horng J. S., Bymaster F. P., Hauser K. L., Molloy B. B. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974 Aug 1;15(3):471–479. doi: 10.1016/0024-3205(74)90345-2. [DOI] [PubMed] [Google Scholar]
  33. Wong D. T., Horng J. S., Fuller R. W. Kinetics of serotonin accumulation into synaptosomes of rat brain--effects of amphetamine and chloroamphetamines. Biochem Pharmacol. 1973 Feb 1;22(3):311–322. doi: 10.1016/0006-2952(73)90412-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES